Compare Harley-Davidson Inc (HOG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Incyte Corporation — how do they compare? Harley-Davidson Inc trades at $27.42 (market cap $2.72B), while Incyte Corporation trades at $120.45 (market cap $24.65B). The key difference: Incyte Corporation is far larger — about 9.1× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.82% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| HOG | INCY | |
|---|---|---|
Market Cap | $2.72B | $24.65B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $129.93 |
52-Week Low | $17.19 | $81.61 |
Enterprise Value | $3.13B | $20.15B |
Dividend Yield | 2.82% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
